Core Viewpoint - The company reported a steady growth in revenue and net profit for the first half of 2025, with a focus on expanding its market presence and enhancing brand recognition through strategic initiatives [1][4]. Financial Performance - In 25H1, the company achieved operating revenue of 2.042 billion yuan, a year-on-year increase of 2.57%, and a net profit attributable to shareholders of 161 million yuan, up 4.30% year-on-year [1]. - The second quarter of 2025 saw operating revenue of 1.087 billion yuan, reflecting a year-on-year growth of 4.66%, with a net profit of 92 million yuan, an increase of 1.13% [1]. - The gross profit margin for 25H1 was 33.18%, with a slight increase in the second quarter to 33.27% [3]. Segment Performance - By dosage form, soft capsules generated revenue of 947 million yuan (up 6.47%), gummies at 517 million yuan (up 6.35%), tablets at 189 million yuan (up 33.37%), while beverages and powders saw declines of 20.84% and 36.02%, respectively [1]. - Regionally, the China segment reported revenue of 818 million yuan (down 1.63%), while the Americas and Europe segments grew by 4.26% and 21.96%, respectively [1]. Strategic Initiatives - The company is focusing on developing new consumer markets, with new consumption customer revenue growth exceeding 40% in 25H1, despite challenges in traditional segments [2]. - The Americas division is expanding its gummy business and targeting new customers in Latin America, particularly in Brazil [2]. - The European division is actively pursuing new clients and products, particularly in the UK market [2]. - The Asia-Pacific division is enhancing partnerships with key clients in Australia and preparing for market expansion in Russia and Japan [2]. Brand and Market Development - The company participated in 12 domestic and international forums and exhibitions in 25H1 to enhance brand visibility and industry influence [4]. - Key breakthroughs were achieved in probiotics and anti-aging sectors, with the launch of the EverBio platform and the GRAS certification for its proprietary probiotics [4]. - The company is also focusing on the pet nutrition market, having participated in the Asia Pet Expo in August 2025 [4]. Global Business Resilience - The company's global business strategy has demonstrated resilience, with strong performance in the Americas and Europe despite tariff fluctuations [6]. - The ongoing construction of a factory in Thailand is expected to further enhance the company's market presence in Southeast Asia [6].